NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) reported financial results for the third quarter of fiscal year 2026, showing a 16% year-over-year increase in product revenue to $2.0 million. The company also achieved a record product gross margin of 59.9%, up from 53.9% in the same period last year, reflecting a more favorable sales mix and operational efficiencies. These results underscore NeuroOne's growing traction in the neurological device market and its ability to convert demand into profitable revenue.
During the quarter, NeuroOne received $2.7 million in new product orders, a 43% increase year-over-year, which outpaced recognized revenue and contributed to a backlog of $1.7 million as of June 30, 2026. For the full fiscal year 2026, the company has received $11.2 million in product orders and expects recognized revenue to range between $9.2 million and $10.5 million, depending on manufacturing and shipment timing. This strong order pipeline highlights sustained demand for NeuroOne's OneRF® ablation systems and other products, and the company is working closely with manufacturing partners to maximize shipments through the end of the fiscal year.
A significant operational milestone was the receipt of ISO 13485:2016 certification, which enables NeuroOne to commercialize its products internationally. This certification, achieved ahead of schedule, signals adherence to a globally recognized quality management system and opens near-term commercial opportunities in international markets. The company plans to selectively target countries and is actively planning for international expansion, which could diversify revenue streams and accelerate growth.
In the research arena, a peer-reviewed article published in the Journal of Neurosurgery by the Mayo Clinic in Jacksonville, Florida, evaluated the use of NeuroOne's OneRF® Brain Ablation System in patients with implanted neuromodulation devices. The study concluded that the procedure can be performed safely without interfering with existing hardware and provided meaningful seizure reduction. This expands the treatable patient population to include those with neuromodulation implants, potentially increasing the addressable market for the technology.
NeuroOne also expects its StereoCED™ drug delivery platform to be available for animal research and FDA IDE approved studies by the end of fiscal year 2026. The company released a white paper titled "StereoCED™ - A Scalable Platform for CNS Drug Delivery" highlighting its potential to reduce procedure time and address barriers to commercial delivery of brain therapeutics. This timing is strategic, as the first potential blockbuster intraparenchymal brain-delivered therapy could receive FDA approval as early as 2027, positioning NeuroOne to capitalize on a growing market.
Collaborations with the Mayo Clinic and the University of Minnesota are advancing research using the StereoCED™ platform. The Mayo Clinic study, funded by CURE Childhood Cancer, will evaluate a novel treatment for pediatric diffuse midline glioma, a highly aggressive brain cancer. The University of Minnesota study will test next-generation epilepsy therapies delivered locally into seizure-related brain regions. These partnerships enhance NeuroOne's credibility and provide clinical data that could support future regulatory approvals and adoption.
Financially, NeuroOne reported a net loss of $2.0 million for the quarter, or $0.28 per diluted share, compared to a net loss of $1.5 million in the prior-year quarter. The increased loss was primarily due to higher operating expenses, including selling, general, and administrative costs related to headcount, sales and marketing, and professional fees. As of June 30, 2026, the company had cash and cash equivalents of $2.0 million and no debt. Subsequent to quarter-end, the company raised an additional $1.0 million through its at-the-market offering program, and its lead investor increased ownership from 7.4% to 12.5% of outstanding common stock.
Looking ahead, NeuroOne is advancing several strategic initiatives: expanding the OneRF® Trigeminal Nerve Ablation System through independent distributor reps, selecting a partner for its basivertebral nerve ablation system, and planning for international growth. The company was also added to the Russell Microcap Index in June 2026, which could enhance visibility and attract institutional investors.
With a strong order backlog, expanding product portfolio, and strategic collaborations, NeuroOne is positioned for sustained growth. The company's focus on innovation and operational efficiency, coupled with a favorable regulatory environment, suggests that it is well-equipped to capitalize on the growing demand for minimally invasive neurological treatments.
